Warren Roston, MD, is a board-certified pulmonologist in Los Angeles. He is a voluntary staff member at a major teaching hospital and practices inpatient medicine with a mixed hospitalist- and intensive-care focus. In this profile, he was interviewed regarding his experience as a patient who experienced systemic inflammatory response syndrome in the context of treatment for melanoma with interleukin-2.
Get full access to this article
View all access options for this article.
References
1.
BleyerAO’LearyMBarrRRiesLAG, eds. Cancer Epidemiology in Older Adolescents and Young Adults 15 to 29 Years of Age, Including SEER Incidence and Survival: 1975-2000. NIH pub. No. 06-5767. Bethesda, MD: National Cancer Institute; 2006.
BalchCMBuziadACSoongSJ. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol. 2001;19:3635-3648.
7.
LeeMLTomsuKVon EschenKB. Duration of survival for disseminated malignant melanoma: results of a meta-analysis. Melanoma Res. 2000;10:81-92.
8.
PhanGQAttiaPSteinbergSMWhiteDERosenbergSA. Factors associated with response to high-dose interleukin-2 in patients with metastatic melanoma. J Clin Oncol. 2001;19:3477-3482.
9.
RosenbergSAMuléJJSpiessPJReichertCMSchwarzSL. Regression of established pulmonary metastases and subcutaneous tumor mediated by the systemic administration of high-dose recombinant interleukin. J Exp Med. 1985;161:1169-1188.
